56 Allogeneic stem cell transplantation using high-dose cytarabine combined with G-SCF and TBI as conditioning for chronic myelogenours leukemia (CML) in advanced stage  by Yamazaki, R. et al.
Poster  P resentat ions  - Sess ion  I 
56 
ALLOGENEIC STEM CELL TRANSPLANTATION USING HIGH-DOSE 
CYTARABINE COMBINED WITH G-SCF AND TBI AS CONDITIONING FOR 
CHRONIC MYELOGENOURS LEUKEMIA (CML) IN ADVANCED STAGE 
Yama:aki, R.; Mori, T.; Shimizu, T.; Aisa, Jr~; Ikeda, }~; Okamoto, S. 
Division of Hematology, Department of lntel-md Medicine, Keio Uni- 
versity School of MedMne, Shinjukz*-ku, Tokyo, ffapan. 
The outcome of allogeneic hematopoietic stem cell transplanta- 
tion (allo-HSCT) for CML in advanced stages (accelerated phase 
(AP) and blast crisis (BC)) is extremely poor, although allo-HSCT 
remains as the only curative treatment. We have evaluated the 
efficacy of the conditioning consisting of high-dose cytarabine 
(HDCA) combined with continuous infusion of G-CSF and TBI. 
The addition of G-CSF to HDAC was based on the hypothesis 
that G-CSF may increase the susceptibility of leukemic ells to 
cytarabine. [PATIENTS & METHODS] 13 patients with CML 
in advanced stages (AP=6, BC=7) received the conditioning and all 
were evaluable. Median age at transplant was 39 (range: 22-51). 10 
patients received unrelated BM, 2 patients received related PBSC, 
and one patient received unrelated CB as a source of stem cells. 
Conditioning included TBI (2Gyx6) followed by HDCA alone 
(n=6) or with cychophosphamide (120mg/kg, n=7). HDCA was 
administered at a dose of 2-3g/m2 x4 or x8 doses together with 
continuous infusion of G-CSF (5mcg/kg) starring 12 hours before 
HDCA and continuing until starting final dose of HDCA. GVHD 
prophylaxis was short-term MTX with cyclosporine A for related 
transplant (n=3) or with FK506 for unrelated transplant (n=I0). 
[RESUTLS] As regiment related toxicities, mucositis and con- 
junctivitis were frequent in patients receiving HDCA 3g/m2 x 8 
doses. One died of bacterial infection before engraftment. 
Engraftment was obtained in 12 patients. 7 of 12 patients devel- 
oped in acute GVHD (grades >II), and 8 of 11 evaluable patients 
developed chronic GVHD. With the median follow-up of 16 
months, 3-year overall survival nd disease-free survival were 60% 
and 54.7%, respectively. 7 patients are still alive and in molecular 
remission. Causes of death included extensive chronic GVHD 
(n=2), liver failure (n=l), Pneumocystis carinii pneumonia (n=l), 
bacterial infection (n=l), and leukemia relapse (n=l). [CONCO- 
LUSION] HDCA together with continuous infusion of G-CSF in 
combination with TBI as conditioning may improve the outcome 
of allo-HSCT for CML in advanced stages. 
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REDUCED-INTENSITY CONDITIONING STEM CELL TRANSPLANT (RIC- 
SCT) WITH FLUDARABINE/BUSULFAN/ATG FOR HEMATOPOIETIC 
MALIGNANCIES 
McGui'rk, J.; l, Villiams, C., Barnha~-t, C.; Day, S.; Belt, R.; 
Abhya~kaJ ~,S. . 
Historically, conditioning regimens for allogeneic SCTs are 
associated with significant regimen-related toxicity (RRT) espe- 
cially in patients with advanced age, prior treatment, and underly- 
ing comorbidities. RIC regimens have been shown to allow 
engraftment with decreased RRT. We studied RIC regimens in 
twenty-four patients (median age 54 years; range 21-66). Diseases 
treated were ALL (1), AML (7), CLL (2), CML (2), MDS (2), 
MM (6), and NHL (4). Fifteen patients received stem cells from 
matched sibling donors (MSD), 2 patients from a 1-antigen mis- 
matched sibling, and 7 patients from atched-unrelated donors 
(MUD). Eight patients had received previous SCT. The RIC reg- 
imens consisted of either fludarabine 40mg/m2/d (n=8) or fludara- 
bine 25 mg/m2/d IV (n=16) x 5 doses, busulfan lmg/kg/dose POx 
8 doses, and horse (n=23) 10 mg/kg/d or rabbit-derived (n=l) 1.5 
mg/kg/d antithymocyte globulin x 4 doses. GVHD prophylaxis 
consisted of tacrolimus 0.03 mg/kg/d CIV starting on day -2 and 
methotrexate 5 mg/m 2IVP on days 1, 3, and 6. The median num- 
ber of CD34 + cells transplanted was 8.0 x I0~/kg. Median time to 
neutrophil engraftment was 18 days (range 14-31 days). Donor 
chimerism was established in 88% of patients at day 100, and 82% 
of evaluable patients had greater than 90% donor chimerism at 1 
year. The incidence of grade ii or hig~aer RRT was 12.5% (3 pts), 
and there was one toxic death attributed to fludarabine (40 
mg/m-') toxicity. The 100 day transplant-related mortality was 
14% (3 pts). Grade II or greater aGVHD developed in 24% (5) of 
evaluable patients, while 80% (12) developed cGVHD (exten- 
sive=10). Actuarial estimate of disease-free survival at 12 months 
was 84% (10 pts). These RIC regimens allowed adequate ngraft- 
ment with decreased RRT, however, GVHD, relapse, and infec- 
tious complications caused significant morbidity and mortality. 
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IMPROVING TRANSPLANT REVENUE MANAGEMENT IN A MULTI- 
HOSPITAL TRANSPLANT ENTERPRISE 
Ball, 1(.l; Zawda, E.2; Hamby, N/ ;  Marshall, B /  1. BMT Program, 
Jewish Hospital, Cincimlati, OH; 2. University, Hospital, Cincinnati, 
OH; 3. Health Alliance of Greater Cincim~ati, Cincimzati, OH. 
The Health Alliance of Greater Cincinnati is a six hospital sys- 
tem with three hospitals providing transplant services. The Health 
Alliance was not capturing reimbursement potential in transplant 
billing and collection. A Transplant Revenue Process hnprove- 
ment Team of 15 people was formed including representation 
from administration levels of solid organ and BMT programs, 
Payor Relations, Patient Accounting, Financial Coordinators, 
Registration and Organizational Effectiveness. From July 2001- 
September 2001 this group spent over 24 meeting hours and 100 
work hours studying current processes, determining areas of 
opportunity and making recommendations. Four recommenda- 
tions were made: 1) Create a specialized position, Transplant 
Operations Analyst (TOA) to manage all patient/donor accounts. 
2) Create an integrated database from the three xisting transplant 
databases allowing the TOA to remain apprised of all new 
patients. 3) Create/implement transplant-specific identification 
cards for patients and donors in order to register them correctly. 
4) Create a Transplant Underpayment Recovery Unit to review 
all underpaid transplants for the past 18 months. Results: A second 
TOA position was needed. The database was enhanced to track 
other costs and allow the TOA to report on any transplant popu- 
lation at any time. The ID cards are invaluable in the traeldng 
process. Of the initial $5,112,433 in underpaid claims, over 
$4,200,000 was collected (118% of the original goal of 
$3,570,000). There are only 261 organ transplant hospitals among 
the over 5,000 acute care hospitals in the US placing organ trans- 
plant hospitals in a highly specialized area. The disciplined 
approach to transplant revenue management processes and the 
significant collaboration of the multidisciplinary transplant busi- 
ness team has positively affected the bottom line. 
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MEDI-TRANSPLANTATION AFTER INTERMEDIATE INTENSITY OF BU 
(12MG) /CY (120MG) CONDITIONING REGIMEN 
Lilt D.; Seiter, K.; Qm'eshi, .4.; Siddiqui, .4.; C,~iao, J.; Ahmed, 72 
New york 3~leclical College and Arlin Cancer Institute, Valhalla, N} ~. 
Non-myeloablative Stem Cell Transplantation (NST) has lower 
morbidity and mortality when compared with transplantation fol- 
lowing conventional conditioning with Bu (16mg)/Cy (120rag) 
regimen. However, quick relapse and/or fast disease progression 
following NST is often a concern for aggressive diseases uch as 
poor prognostic Leukemia, MDS and high grade lymphoma. In an 
attempt o reduce toxicity yet at the same time to preserve the 
dose-intensity, we have reduced the dose of busulfan to 12 mg/kg 
from 16 mg/kg in combination with 120 mg/kg cyclophosphamide 
(Medi-transplant regimen) for patients with AML in advanced 
relapsf and/or with poor prognostic features. Cyclosporine and 
Mycophenolate were used for GVHD prophylaxis. 6 patients (age 
27-53) with AML (3 in 2nd refractory relapse, 2 in 2nd CR, one 
first cytogenetic relapse with Ph+ chromosome) underwent the 
medi transplantation. Three were sibling donors, two were 
matched-unrelated graft, another was 5/6 unrelated graft. All 6 
engrafted promptly with full donor chimerism at engraftment. 
Mild acute GVHD was seen in related transplants, evere GVHD 
was seen in the unrelated grafts. Overall, acute complications are 
less severe. Engraftment with full donor chimerism for both relat- 
ed and unrelated grafts were readily achievable. 
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